Tumor necrosis factor (TNF) inhibitors led to no significant difference in survival or respiratory-related hospitalizations compared with non-TNF inhibitors, in patients with rheumatoid ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results